pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL MYERS SQUIBB · news · pharmadog
← back to BRISTOL MYERS SQUIBB
News mentioning BRISTOL MYERS SQUIBB
100
stories
11d
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
biospace
12d
AI data becomes sticking point in biopharma dealmaking
biospace
12d
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
biopharma dive
12d
Is there an exodus underway at Epic?
stat
13d
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
fiercebiotech
13d
FDA still focused on lettuce supplier as source of parasite, despite faulty test result
stat
13d
STAT+: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and more
stat
13d
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
biopharma dive
13d
Bristol Myers, Nvidia say they'll build 'most powerful' AI supercomputer in pharma
endpoints
13d
STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer
stat
13d
BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’
fiercebiotech
14d
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
16d
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech
17d
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
17d
Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
fiercebiotech
17d
Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
fiercebiotech
17d
Opinion: The growing fang-to-pharmacy pipeline
stat
18d
Braveheart, Attovia join next wave of biotech IPOs
biopharma dive
20d
Agenus surges on study pivot; Apnimed lines up an IPO
biopharma dive
27d
Bristol Myers details Krazati confirmatory study failure in colorectal cancer
endpoints
Jul 2, 26
A PureTech startup banks $180M for a new IPF drug
biopharma dive
Jul 2, 26
Roche KRAS drug succeeds in head-to-head lung cancer study
biopharma dive
Jul 2, 26
Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study
endpoints
Jul 1, 26
Abivax shares surge as worries subside over immune drug’s cancer risk
biopharma dive
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 30, 26
Beeline ups its Series A round for immune drug work
biopharma dive
Jun 30, 26
Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
endpoints
Jun 30, 26
House China panel probes Bristol Myers, Pfizer on use of trial sites
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 26, 26
At BIO, tension over China biotech deal regulation looms
biopharma dive
← prev
page 2 of 4
next →
